4382 | BEDSIDE
Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial
C.E. Svenningsen1, J. Engdahl1, V. Frykman-Kull1, L. Friberg1, L.A. Levin2, M. Rosenberg1,1 Karolinska Institute, Danderyd Hospital, Department of Clinical Sciences, Stockholm, 2 Central Hospital, Halmstad, 3 Linkoping University, Department of Medical and Health Sciences, Linkoping, Sweden

Background: Atrial fibrillation (AF) is a frequent source of cardiac emboli in patients with ischemic stroke. AF may be asymptomatic and therefore undiagnosed. As oral anticoagulation (OAC) treatment is highly effective for stroke prevention, screening for silent AF seems suitable in risk populations. Above the age of 75, the current guidelines recommend OAC for AF, even in the absence of other risk factors. We hypothesize that AF screening in this age group will reduce stroke incidence.

Methods: All inhabitants in Stockholm County and Region Halland, Sweden age 75-76 years (n=25 415) are randomized in a 1:1 fashion either to be invited to a screening program for AF or to act as a control group. In the screening group, participants are invited to undergo intermittent ambulatory ECG recordings during two weeks. Participants in whom AF is detected are offered OAC treatment. Screening-and control groups will be followed prospectively for 5 years with regard to thromboembolic events, bleeding and mortality.

Results: During a 10-month period, 10 503 inhabitants in the screening arm had been invited and 4783 (46%) participated. Previously undiagnosed AF was found in 131 (3%) of participants and another 85 (2%) have been identified with AF in the screening group. Participation in the screening program is lower in urban Stockholm (45%) in comparison to rural areas (64%). More than 90% of the patients with undiagnosed AF were started on OAC.

Conclusion: Population based AF screening in a 75-year old population identifies 5% of the population as new candidates for OAC treatment due to AF. There is considerable local and regional variation in participation in the screening program.

4383 | BEDSIDE
Dabigatran use in Danish atrial fibrillation patients in 2011: preliminary results from the STROKESTOP trial
1 Bispebjerg Hospital, Copenhagen, Denmark; 2 Copenhagen University Hospital Gentofte, Department of Cardiology, Copenhagen, Denmark; 3 Aalborg Hospital, Aarhus University Hospital, Department of Cardiology, Aalborg, Denmark; 4 Rigshospitalet - University Hospital, Copenhagen, Denmark; 5 Hilleord Hospital, Department of Cardiology and Endocrinology, Hilleord, Denmark; 6 University of Birmingham, Centre for Cardiovascular Sciences, City Hospital, Birmingham, United Kingdom

Purpose: Dabigatran was recently approved for anticoagulation in patients with Atrial Fibrillation (AF); data regarding real-world use, comparative effectiveness, and safety is sparse.

Methods: From nationwide registers, we identified patients with an in hospital or outpatient-clinic AF diagnosis who claimed a prescription of dabigatran 110 or 150 mg, or warfarin, between August 22nd and December 31st, 2011. Hazard ratios of thromboembolic events (ischemic stroke, transient ischemic attack, and peripheral artery embolism) and bleedings were estimated using Cox regression analyses, in all patients and stratified by previous Vitamin K antagonist (VKA) use, defined as a claimed prescription of warfarin 180 days before the AF diagnosis. Results: Overall, 1,612 (31%) and 1,114 (21.1%) claimed a prescription of dabigatran 110 mg and 150 mg, and 49,640 (84.8%) of warfarin. Patients treated with dabigatran 150 mg were younger with less comorbidity than those treated with dabigatran 110 mg and warfarin, as was VKA naive compared with VKA experienced patients. Recommendations set by the European Medicine Agency for dabigatran were met in 90.3% and 55.5% of patients treated with 110 mg and 150 mg. Patients treated with 150 mg dabigatran, who did not fulfill the recommendation by European Medicine Agency were > 80 years (3.8%), patients with liver (1.5%) and kidney (3.2%) disease, and patients with previous bleeding (7.0%). Compared with the 110 mg warfarin and the VKA naive patients a decreased risk was found in VHD patients with dabigatran 110 mg, but not in patients with 150 mg dabigatran, nor in the VKA naive users.

Conclusion: Deviations from recommended use of dabigatran were frequent among patients treated with 150 mg. With cautious interpretation, dabigatran use in VKA naive patients seems safe. Increased risk of thromboembolism and bleeding with dabigatran amongst VKA experienced users may reflect patient selection and “drug switching” practices.

4384 | BEDSIDE
Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease: findings from the ARISTOTLE study
1 Dante Pazzanese Institute of Cardiology, Sao Paulo, Brazil; 2 Duke University Medical Center, Duke Clinical Research Institute, Durham, United States of America; 3 University of La Frontera, Temuco, Chile; 4 Bristol-Myers Squibb, Princeton, United States of America; 5 St. John’s Medical College, Bangalore, India; 6 Ankara University, Ankara, Turkey; 7 Estudios Cardiologicos Latinoamericanos (ECLA), Rosario, Argentina

Purpose: Apixaban is indicated for the prevention of stroke and systemic embolism (SE) in pts with non-valvular AF. In this context, valvarus refers only to clinically significant mitral stenosis (MS) and not other valvarus heart disease (VHD). Little is known about the efficacy and safety of apixaban in pts with AF and VHD.

Methods: We used data from 18,197 pts with AF and ≥1 risk factor for stroke in ARISTOTLE with available information on VHD. Pts with clinically significant MS and mechanical heart valves were not eligible. Of these, 4808 (26.4%) had VHD defined by any history of at least moderate mitral regurgitation (3526), MS (131), aortic regurgitation (867), aortic stenosis (384), tricuspid regurgitation (2124), or valve surgery (251). We compared the effect of apixaban vs. warfarin on rates of stroke or SE and major bleeding in pts with and without VHD using Cox proportional hazards modeling.

Results: Pts with VHD were older, had more prior MI and prior bleeding, had a higher mean CHADS2 score, and had less hypertension and diabetes than pts without VHD. Pts with VHD had higher rates of stroke or SE and bleeding than pts without VHD. The benefits of apixaban compared with warfarin in reducing stroke and SE (interaction p=0.03), causing less major bleeding (interaction p=0.23), and decreasing death (interaction p=0.10) were consistent irrespective of the presence of VHD (Fig).

Conclusions: Pts with AF and VHD are at high risk for thromboembolic events and bleeding. Apixaban was similarly efficacious and safe in AF pts with and without VHD. Additional research is needed on the efficacy and safety of apixaban in pts with AF and VHD, particularly those with clinically significant MS and prosthetic valves.

4385 | BEDSIDE
Efficacy and safety of rivaroxaban compared with warfarin in patients with peripheral artery disease and non-valvular atrial fibrillation: insights from ROCKET AF
W.S. Jones1, A.S. Hellkamp1, J. Halperin1, J.P. Piccini1, G. Breithardt2, D.E. Singer3, K.A.A. Fox4, K.W. Mahaffey2, M.R. Patel5 on behalf of the ROCKET AF. 1 Duke University School of Medicine, Durham, NC, United States of America; 2 Mount Sinai Medical Center, New York, NY, United States of America; 3 University of Munster, Department of Cardiovascular Diseases in Adult, Munster, Germany; 4 Harvard Medical School, Massachusetts General Hospital, Boston, United States of America; 5 University of Edinburgh, Edinburgh, United Kingdom

Purpose: We performed a post-hoc analysis of the association between peripheral artery disease (PAD) and outcomes in AF patients and the safety and efficacy of rivaroxaban in AF patients with PAD. Methods: ROCKET AF was a double-blind, double-dummy, randomized con-